The synergistic role of gut microbiota and RNA in metabolic diseases: mechanisms and therapeutic insights DOI Creative Commons
Zhuo Huang, Qinyan Yao,

Shuang Ma

et al.

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 29, 2025

The gut microbiota plays a pivotal role in human metabolic health by influencing immune responses, digestion, and homeostasis. Recent research highlights the intricate interactions between RNA, especially non-coding RNAs, regulating processes. Dysbiosis of has been linked to disorders such as type 2 diabetes, obesity, metabolic-associated fatty liver disease (MAFLD) heart disease. Microbial metabolites, including short-chain acids (SCFAs), modulate RNA expression, lipid metabolism, glucose regulation, inflammatory responses. Additionally, microRNAs (miRNAs) long RNAs (lncRNAs) serve critical regulators these processes, with emerging evidence showing that gut-derived metabolites affect post-transcriptional gene regulation. This review synthesizes current understanding microbiota-RNA axis its diseases. By exploring molecular mechanisms, particularly how microbiota-derived signals pathways, underscores potential targeting this for therapeutic interventions. Furthermore, it examines dysbiosis leads epigenetic changes m6A methylation, contributing pathogenesis. These insights offer new perspective on prevention treatment diseases, applications personalized medicine.

Language: Английский

The synergistic role of gut microbiota and RNA in metabolic diseases: mechanisms and therapeutic insights DOI Creative Commons
Zhuo Huang, Qinyan Yao,

Shuang Ma

et al.

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 29, 2025

The gut microbiota plays a pivotal role in human metabolic health by influencing immune responses, digestion, and homeostasis. Recent research highlights the intricate interactions between RNA, especially non-coding RNAs, regulating processes. Dysbiosis of has been linked to disorders such as type 2 diabetes, obesity, metabolic-associated fatty liver disease (MAFLD) heart disease. Microbial metabolites, including short-chain acids (SCFAs), modulate RNA expression, lipid metabolism, glucose regulation, inflammatory responses. Additionally, microRNAs (miRNAs) long RNAs (lncRNAs) serve critical regulators these processes, with emerging evidence showing that gut-derived metabolites affect post-transcriptional gene regulation. This review synthesizes current understanding microbiota-RNA axis its diseases. By exploring molecular mechanisms, particularly how microbiota-derived signals pathways, underscores potential targeting this for therapeutic interventions. Furthermore, it examines dysbiosis leads epigenetic changes m6A methylation, contributing pathogenesis. These insights offer new perspective on prevention treatment diseases, applications personalized medicine.

Language: Английский

Citations

0